These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19170302)

  • 1. A prospective baseline versus on-treatment study assessing patient perceptions of using a smaller needle when injecting intramuscular interferon beta-1 a (Avonex).
    Freedman SM; Cox D; Rosebrough T
    J Neurosci Nurs; 2008 Dec; 40(6):350-5. PubMed ID: 19170302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
    Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
    BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a.
    Limmroth V; Gerbershagen K
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1969-78. PubMed ID: 25255732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
    Hupperts R; Becker V; Friedrich J; Gobbi C; Salgado AV; Sperling B; You X
    Expert Opin Drug Deliv; 2015 Jan; 12(1):15-25. PubMed ID: 25430947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A; Murray TJ;
    Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications.
    Mohr DC; Cox D; Merluzzi N
    Mult Scler; 2005 Apr; 11(2):182-5. PubMed ID: 15794392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of EMLA cream to reduce fear and pain associated with interferon beta-1a injection in patients with multiple sclerosis.
    Buhse M
    J Neurosci Nurs; 2006 Aug; 38(4):222-6. PubMed ID: 16924997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
    O'Connor P;
    Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.
    Rudick RA; Pace A; Rani MR; Hyde R; Panzara M; Appachi S; Shrock J; Maurer SL; Calabresi PA; Confavreux C; Galetta SL; Lublin FD; Radue EW; Ransohoff RM
    Neurology; 2009 Jun; 72(23):1989-93. PubMed ID: 19506220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis.
    Jaber A; Bozzato GB; Vedrine L; Prais WA; Berube J; Laurent PE
    BMC Neurol; 2008 Oct; 8():38. PubMed ID: 18845005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological and clinical profile of IFNbeta-1a (Avonex IM Injection Syringe 30 microg].
    Sumino R
    Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):209-17. PubMed ID: 17379973
    [No Abstract]   [Full Text] [Related]  

  • 12. Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age.
    Lampl C; You X; Limmroth V
    Eur J Neurol; 2012 Jan; 19(1):142-8. PubMed ID: 21718390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
    Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.
    Phillips JT; Rice G; Frohman E; Vande Gaer L; Scott T; Haas J; Eggenberger E; Freedman MS; Stuart W; Cunha L; Jacobs L; Oger J; Arnold D; Murray TJ; DiBiase M; Jethwa V; Goelz S
    Clin Ther; 2004 Apr; 26(4):511-21. PubMed ID: 15189748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis.
    Turner AP; Williams RM; Sloan AP; Haselkorn JK
    Rehabil Psychol; 2009 Feb; 54(1):116-21. PubMed ID: 19618711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results.
    Ghezzi A; Amato MP; Capobianco M; Gallo P; Marrosu MG; Martinelli V; Milanese C; Moiola L; Milani N; La Mantia L; Patti F; Pozzilli C; Trojano M; Comi G; Zaffaroni M;
    Neurol Sci; 2007 Jun; 28(3):127-32. PubMed ID: 17603763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will new injection devices for interferon β-1a s.c. affect treatment adherence in patients with multiple sclerosis? An expert opinion in the Middle East.
    Deleu D; Alsharoqi I; Al Jumah MA; Al Tahan AR; Bohlega S; Dahdaleh M; Inshasi J; Khalifa A; Szólics M; Yamout BI
    Int J Neurosci; 2011 Apr; 121(4):171-5. PubMed ID: 21329472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to therapy: using an evidence-based protocol.
    Moore LA; Kaufman MD; Algozzine R; Irish N; Martin M; Posey CR
    Rehabil Nurs; 2007; 32(6):227-32. PubMed ID: 18065143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.
    O'Connor P; Kinkel RP; Kremenchutzky M
    Mult Scler; 2009 Jun; 15(6):728-34. PubMed ID: 19482863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.